- Home
- BWB vs SGHT Comparison
BWB vs SGHT Comparison
Compare BWB & SGHT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BWB
- SGHT
- Stock Information
- Founded
- BWB 2005
- SGHT 2011
- Country
- BWB United States
- SGHT United States
- Employees
- BWB N/A
- SGHT N/A
- Industry
- BWB Major Banks
- SGHT Medical Specialities
- Sector
- BWB Finance
- SGHT Health Care
- Exchange
- BWB Nasdaq
- SGHT Nasdaq
- Market Cap
- BWB 365.0M
- SGHT 140.1M
- IPO Year
- BWB 2018
- SGHT 2021
- Fundamental
- Price
- BWB $13.76
- SGHT $2.47
- Analyst Decision
- BWB Strong Buy
- SGHT Buy
- Analyst Count
- BWB 2
- SGHT 7
- Target Price
- BWB $17.50
- SGHT $3.83
- AVG Volume (30 Days)
- BWB 44.9K
- SGHT 330.9K
- Earning Date
- BWB 04-23-2025
- SGHT 03-05-2025
- Dividend Yield
- BWB N/A
- SGHT N/A
- EPS Growth
- BWB N/A
- SGHT N/A
- EPS
- BWB 1.03
- SGHT N/A
- Revenue
- BWB $106,036,000.00
- SGHT $79,866,000.00
- Revenue This Year
- BWB $26.46
- SGHT $3.09
- Revenue Next Year
- BWB $12.13
- SGHT $13.61
- P/E Ratio
- BWB $13.48
- SGHT N/A
- Revenue Growth
- BWB N/A
- SGHT N/A
- 52 Week Low
- BWB $10.52
- SGHT $2.17
- 52 Week High
- BWB $16.00
- SGHT $8.45
- Technical
- Relative Strength Index (RSI)
- BWB 45.62
- SGHT 50.28
- Support Level
- BWB $13.52
- SGHT $2.25
- Resistance Level
- BWB $14.21
- SGHT $2.58
- Average True Range (ATR)
- BWB 0.32
- SGHT 0.28
- MACD
- BWB -0.08
- SGHT 0.03
- Stochastic Oscillator
- BWB 31.44
- SGHT 68.42
About BWB Bridgewater Bancshares Inc.
Bridgewater Bancshares Inc offers retail and commercial loan and deposit services to customers within the Minneapolis-St. Paul-Bloomington, MN-WI Metropolitan Statistical Area. The company engages in providing a wide range of deposit and lending products. Its products and services include commercial deposits, loans, online business services, credit card, mobile banking, and remote deposit services.
About SGHT Sight Sciences Inc.
Sight Sciences Inc is an ophthalmic medical device company focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. Its Surgical Glaucoma segment's product portfolio features the OMNI Surgical System, a device that facilitates the performance of both canaloplasty and trabeculotomy with a single device and single corneal incision to reduce intraocular pressure in adult patients with primary open-angle glaucoma. The company's Dry Eye segment's product portfolio consists of the TearCare System for ophthalmologists and optometrists. It derives key revenue from the Surgical Glaucoma segment.